Lys323
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys323  -  Myc (mouse)

Site Information
RKDYPAAkRAKLDsG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 458888

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 2 ) , mass spectrometry ( 2 ) , modification-specific antibody ( 1 ) , mutation of modification site ( 2 ) , peptide sequencing ( 2 ) , western blotting ( 1 , 2 )
Disease tissue studied:
lung cancer ( 2 ) , non-small cell lung cancer ( 2 )
Relevant cell line - cell type - tissue:
3T3-L1 (fibroblast) ( 1 ) , fibroblast-embryo ( 1 ) , NCI-H1299 (pulmonary) ( 2 ) , preadipocyte ( 1 )

Upstream Regulation
Treatments:
siRNA ( 1 )

Downstream Regulation
Effects of modification on Myc:
activity, induced ( 1 ) , protein stabilization ( 2 )
Effects of modification on biological processes:
cell differentiation, induced ( 1 ) , cell growth, induced ( 1 ) , transcription, induced ( 2 )

References 

1

Abdesselem H, et al. (2016) SIRT1 Limits Adipocyte Hyperplasia through c-Myc Inhibition. J Biol Chem 291, 2119-35
26655722   Curated Info

2

Patel JH, et al. (2004) The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60. Mol Cell Biol 24, 10826-34
15572685   Curated Info